STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARDT
  4. [8-K] Ardent Health, Inc. Reports Material Event

Ardent Health (ARDT) hospital services president exits under severance plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ardent Health, Inc. reported that Ethan Chernin, its President, Hospital Services, departed the company effective March 24, 2026. The company classified his departure as a “Qualifying Termination” under its Executive Severance Plan, meaning he will receive severance and related benefits subject to that plan’s terms.

Details of the severance framework are described in Ardent Health’s 2025 proxy statement and in the Executive Severance Plan previously filed as an exhibit to a Form 10-Q for the quarter ended June 30, 2024.

Positive

  • None.

Negative

  • None.

Insights

Key hospital division leader departs under standard severance terms.

Ardent Health, Inc. disclosed that Ethan Chernin, President, Hospital Services, left the company effective March 24, 2026. The role appears to be a senior operational position overseeing hospital services, making the change relevant for organizational continuity and execution in that segment.

The company classified the event as a “Qualifying Termination” under its Executive Severance Plan, so severance will follow pre-established rules rather than ad hoc negotiation. This suggests a structured approach to executive exits, with economic terms already outlined in prior proxy and 10-Q disclosures.

The filing does not discuss succession, interim leadership, or strategic implications. Future company filings may provide more context on who will assume responsibility for hospital services and whether the departure coincides with any change in operating strategy or performance expectations.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

What executive change did Ardent Health (ARDT) disclose in this 8-K?
Ardent Health disclosed that Ethan Chernin, its President, Hospital Services, departed effective March 24, 2026. The company and Mr. Chernin determined he would no longer serve in that role, and his exit triggered treatment as a “Qualifying Termination” under the Executive Severance Plan.

When did Ethan Chernin’s employment with Ardent Health (ARDT) end?
Ethan Chernin’s employment ended effective March 24, 2026. On that date, Ardent Health and Mr. Chernin determined he would no longer serve as President, Hospital Services, and he departed the company, with his separation handled under the terms of the Executive Severance Plan.

How is Ethan Chernin’s departure from Ardent Health (ARDT) classified?
His departure is classified as a “Qualifying Termination” under Ardent Health’s Executive Severance Plan. This classification governs the severance and related benefits he is eligible to receive, tying his exit to predefined conditions and formulas rather than a bespoke separation agreement.

What severance will Ethan Chernin receive from Ardent Health (ARDT)?
He will receive severance and related benefits determined by Ardent Health’s Executive Severance Plan. The exact amounts and benefit details are not restated here but are described in the company’s 2025 proxy statement and the plan filed as an exhibit to its June 30, 2024 Form 10-Q.

Where can investors find details on Ardent Health’s Executive Severance Plan?
Details are provided in Ardent Health’s proxy statement for its 2025 Annual Meeting of Stockholders and in the Executive Severance Plan filed as an exhibit to its Form 10-Q for the quarter ended June 30, 2024, both available through the Securities and Exchange Commission’s EDGAR system.

Does the Ardent Health (ARDT) filing name a successor to the President, Hospital Services role?
The filing does not name a successor to the President, Hospital Services role. It focuses on disclosing Ethan Chernin’s departure and confirming that his separation qualifies under the Executive Severance Plan, without discussing replacement plans or interim leadership arrangements for hospital services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
8-KFALSE0001756655340 Seven Springs WaySuite 100BrentwoodTennessee00017566552026-03-242026-03-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2026 (March 24, 2026)

ARDENT HEALTH, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-4218061-1764793
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
340 Seven Springs Way, Suite 100, Brentwood, Tennessee
37027
(Address of Principal Executive Offices)(Zip Code)
(615) 296-3000
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $.01 par value per shareARDTNew York Stock Exchange
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  o
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o



Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 24, 2026, Ardent Health, Inc. (the “Company”) and Ethan Chernin determined that Mr. Chernin would no longer serve as President, Hospital Services and would depart the Company effective that day. The Company treated Mr. Chernin’s departure from the Company as a “Qualifying Termination” pursuant to the Company’s Executive Severance Plan (the “Severance Plan”). Mr. Chernin will be entitled to receive severance and related benefits for such a separation, subject to compliance with the terms and conditions of the Severance Plan. The severance and related benefits under the Severance Plan are described further in the proxy statement for the Company’s 2025 Annual Meeting of Stockholders, filed on Schedule 14A with the Securities and Exchange Commission on April 8, 2025, and in the Severance Plan, filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2024 filed with the Securities and Exchange Commission on August 14, 2024.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Dated: March 27, 2026    
ARDENT HEALTH, INC.
By:
/s/ Stephen C. Petrovich
Name:
Stephen C. Petrovich
Title:
Executive Vice President & General Counsel


Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents